The aim of this study was to investigate the mechanism of propranolol on the regression of hemangiomas. Propranolol-treated hemangioma tissues were collected and the expression of hypoxia inducible factor-1α (HIF-1α) was examined. We also established HIF-1α overexpression and knockdown hemangioma cells, and determined the effects of HIF-1α on the hemangioma cells proliferation, apoptosis, migration and tube formation. Significantly increased HIF-1α level was found in the hemangioma tissues compared to that in normal vascular tissues, whereas propranolol treatment decreased the HIF-1α level in hemangioma tissues in a time- and dose-dependent manner. Moreover, propranolol treatment significantly decreased cell proliferation, migration and tub...
Hemangiomas are indolent birthmarks of vascular origin, which are known to appear soon after birth, ...
Background: Propranolol (antagonist of β1-/β2-AR but minimally active against β3-AR) is currently th...
Touchant près de 3 à 10 % des nouveau-nés, les hémangiomes infantiles (HI) sont des tumeurs vasculai...
Objective To investigate the effects of propranolol on the expression of growth factors and apoptoti...
Objective. Infantile hemangiomas (IHs) are the most common benign tumors in infancy. The purpose of ...
Hemangioma (HA) is one of the most common benign vascular tumors among children. Propranolol is used...
Infantile hemangioma (IH) is the most common tumour of infancy. The recommended treatment for IH is ...
Background: Infantile hemangioma (IH) is the most common tumor of infancy. The first-line therapy fo...
Infantile hemangioma is a common tumor of infancy. Although most hemangiomas spontaneously regress, ...
Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infanti...
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau...
28 p.-9 fig.The β-blocker propranolol, originally designed for cardiological indications (angina, ca...
13 p.-7 fig.One of the major consequences of the lack of a functional VHL protein in von Hippel-Lind...
The mechanisms underlying the success of propranolol in the treatment of infantile hemangioma (IH) r...
Xin Tan, Shu Guo, Chenchao Wang Department of Plastic Surgery, First Hospital of China Medical Unive...
Hemangiomas are indolent birthmarks of vascular origin, which are known to appear soon after birth, ...
Background: Propranolol (antagonist of β1-/β2-AR but minimally active against β3-AR) is currently th...
Touchant près de 3 à 10 % des nouveau-nés, les hémangiomes infantiles (HI) sont des tumeurs vasculai...
Objective To investigate the effects of propranolol on the expression of growth factors and apoptoti...
Objective. Infantile hemangiomas (IHs) are the most common benign tumors in infancy. The purpose of ...
Hemangioma (HA) is one of the most common benign vascular tumors among children. Propranolol is used...
Infantile hemangioma (IH) is the most common tumour of infancy. The recommended treatment for IH is ...
Background: Infantile hemangioma (IH) is the most common tumor of infancy. The first-line therapy fo...
Infantile hemangioma is a common tumor of infancy. Although most hemangiomas spontaneously regress, ...
Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infanti...
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau...
28 p.-9 fig.The β-blocker propranolol, originally designed for cardiological indications (angina, ca...
13 p.-7 fig.One of the major consequences of the lack of a functional VHL protein in von Hippel-Lind...
The mechanisms underlying the success of propranolol in the treatment of infantile hemangioma (IH) r...
Xin Tan, Shu Guo, Chenchao Wang Department of Plastic Surgery, First Hospital of China Medical Unive...
Hemangiomas are indolent birthmarks of vascular origin, which are known to appear soon after birth, ...
Background: Propranolol (antagonist of β1-/β2-AR but minimally active against β3-AR) is currently th...
Touchant près de 3 à 10 % des nouveau-nés, les hémangiomes infantiles (HI) sont des tumeurs vasculai...